ATHE | Alterity Therapeutics Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.40 - 3.49
52 Week Range	1.0000 - 5.87
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	8,840
Average Volume	456,101
Shares Outstanding	10,685,800
Market Cap	36,866,010
Sector	Healthcare
Industry	Biotechnology
IPO Date	2003-09-29

Valuation
Profitability
Growth
Health
P/E Ratio	-2.28
Forward P/E Ratio	N/A
EPS	-1.51
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	Australia
Website	ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ATHE's peers: ANEB, PMVP, ANTX, ELYM, HCWB, TARA, VCNX, MNPR, MIRO, SRZN, NBY, ABIO, QNRX, ARTL, ADIL, RNAZ, ADTX, RVPH, ATXI, ENTX

*Chart delayed

Analyzing fundamentals for ATHE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ATHE Fundamentals page.

Watching at ATHE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ATHE Technicals page.